

Technology Advisory Committee A Interests Register

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]

Publication Date: 23 February 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Ms Becky Pennington	TA Committee A Member	Direct - financial	Currently receives consultancy fees for working on a methods research project for Takeda, manufacturer of a comparator drug. The project started in January 2021 and is expected to conclude in July 2021. The project is not specific to any Takeda product or indication, including Hodgkin lymphoma.	NA	08/03/2021	July 2021	It was agreed that this declaration would not prevent Ms Pennington from participating in this section of the meeting.
Mr Dominic Pivonka	TA Committee A Member	Indirect interest	Employer, AbbVie, has treatments being investigated in early phase studies for haematologic and solid tumours. These are not yet licensed. AbbVie has licensed and late-stage treatments in an unrelated haematologic cancers.	NA	11/03/2021	NA	It was agreed that this declaration would not prevent Mr Pivonka from participating in this section of the meeting.

Dr Alice Turner	TA Committee A Member	Direct non-financial professional interest	Currently has a grant undergoing contract with MSD in an unrelated disease area (refractory chronic cough; RCC). Dr Turner is also the UK co-ordinating investigator on a trial for MSD in RCC. In both cases, payments go to Dr Turner's institution.	NA	05/02/2021	NA	It was agreed that this declaration would not prevent Dr Turner from participating in this section of the meeting.
Dr Graham Collins	Clinical Expert	Direct & Indirect - financial	Received honoraria from Takeda for advisory and speaker work.	NA	11/08/2020	NA	It was agreed that this declaration would not prevent Dr Collins from providing expert advice to the committee.
			MSD provided him with research support and drugs free of charge for the clinical trial he was running. Received honoraria from MSD over 2 years ago for consultancy work.	NA	07/10/2020	NA	It was agreed that this declaration would not prevent Dr Collins from providing expert advice to the committee.
Mr Stephen Scowcroft	Patient Expert	Indirect interests	Mr Scowcroft's employer, Lymphoma Action, receives grant funding from a number of pharmaceutical organisations to support information and education activities. No organisation has any direct editorial into Lymphoma Action's activities.	NA	26/03/2021	NA	It was agreed that this declaration would not prevent Mr Scowcroft from providing expert advice to the committee.

